FCGR3A and neoplasm: These features, along with their amplified responses to antibody-coated target cells and in vitro expansion capability via CD16, may well support tumor-targeting mAb-dependent tumor clearance and the generation of antitumor adaptive immune responses that may provide long-term protection of mAb-treated patients.